GOVX vs. BCEL, PHIO, ALZN, REVB, CLVR, EVOK, PHAS, ARTL, ENSC, and LGVN
Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Atreca (BCEL), Phio Pharmaceuticals (PHIO), Alzamend Neuro (ALZN), Revelation Biosciences (REVB), Clever Leaves (CLVR), Evoke Pharma (EVOK), PhaseBio Pharmaceuticals (PHAS), Artelo Biosciences (ARTL), Ensysce Biosciences (ENSC), and Longeveron (LGVN). These companies are all part of the "pharmaceutical preparations" industry.
GeoVax Labs (NASDAQ:GOVX) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and community ranking.
In the previous week, GeoVax Labs had 6 more articles in the media than Atreca. MarketBeat recorded 6 mentions for GeoVax Labs and 0 mentions for Atreca. GeoVax Labs' average media sentiment score of 0.47 beat Atreca's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.
GeoVax Labs currently has a consensus target price of $120.00, indicating a potential upside of 6,679.66%. Given GeoVax Labs' stronger consensus rating and higher probable upside, research analysts plainly believe GeoVax Labs is more favorable than Atreca.
Atreca received 84 more outperform votes than GeoVax Labs when rated by MarketBeat users. However, 91.67% of users gave GeoVax Labs an outperform vote while only 67.86% of users gave Atreca an outperform vote.
GeoVax Labs has higher revenue and earnings than Atreca. GeoVax Labs is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.
GeoVax Labs has a beta of 2.91, indicating that its share price is 191% more volatile than the S&P 500. Comparatively, Atreca has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.
6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 37.5% of Atreca shares are held by institutional investors. 5.7% of GeoVax Labs shares are held by insiders. Comparatively, 11.3% of Atreca shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Atreca's return on equity of -157.90% beat GeoVax Labs' return on equity.
Summary
GeoVax Labs beats Atreca on 9 of the 16 factors compared between the two stocks.
Get GeoVax Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GeoVax Labs Competitors List
Related Companies and Tools
